World's Best Scientists 2026 revealed!
Daniel J. George

Daniel J. George

Daniel J. George publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel J. George sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Daniel J. George D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel J. George sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Daniel J. George is affiliated with Duke University in the United States. Their research spans multiple areas within medicine and biochemistry, genetics, and molecular biology, with a particular focus on oncology and pulmonary medicine.

The scientist's primary fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their subfields of study highlight specific areas:

  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Oncology
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

The main research topics covered by Daniel J. George include:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Cancer, Lipids, and Metabolism
  • Prostate Cancer Diagnosis and Treatment
  • Renal cell carcinoma treatment
  • Cancer Genomics and Diagnostics
  • Hormonal and reproductive studies

Daniel J. George has been published extensively in various journals. Their frequent publication venues are:

  • Journal of Clinical Oncology
  • Prostate Cancer and Prostatic Diseases
  • Cancer Epidemiology Biomarkers & Prevention
  • Annals of Oncology
  • Future Oncology

Among their recent papers are:

  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer, 2020, New England Journal of Medicine
  • Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial, 2022, Journal for ImmunoTherapy of Cancer
  • Novel therapies are changing treatment paradigms in metastatic prostate cancer, 2020, Journal of Hematology & Oncology
  • Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022, 2022, European Urology
  • LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types, 2021, Journal for ImmunoTherapy of Cancer

Frequent co-authors in their research collaborations include:

  • Andrew J. Armstrong
  • Tian Zhang
  • Susan Halabi
  • Neal D. Shore
  • Michael R. Harrison

Best Publications

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;M. Dror Michaelson;Bruce G. Redman;Gary R. Hudes

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Prostate cancer. Clinical practice guidelines in oncology.

    James Mohler;Robert R. Bahnson;Barry Boston;J. Erik Busby

  • Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

    Matthew T. Roe;Paul W. Armstrong;Keith A.A. Fox;Harvey D. White

  • Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

    Alain Ravaud;Robert J. Motzer;Hardev S. Pandha;Daniel J. George

  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Toni K. Choueiri;Susan Halabi;Ben L. Sanford;Olwen Hahn

  • Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.

    Joel B. Nelson;Sean P. Hedican;Daniel J. George;A. H. Reddi

  • Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

    Andrew J. Armstrong;Matthew S. Marengo;Sebastian Oltean;Sebastian Oltean;Gabor Kemeny

  • Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

    Giancarlo Agnelli;Daniel J. George;Ajay K. Kakkar;William Fisher

  • Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions

    T.N. Small;E.B. Papadopoulos;F. Boulad;P. Black

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Andrew J Armstrong;Susan Halabi;Tim Eisen;Samuel Broderick

  • Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

    William Kevin Kelly;Susan Halabi;Michael Carducci;Daniel George

  • Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480

    Daniel J. George;Susan Halabi;Timothy F. Shepard;Nicholas J. Vogelzang

  • Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

    Toni K. Choueiri;Colin Hessel;Susan Halabi;Ben Sanford

  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

    Neal D. Shore;Fred Saad;Michael S. Cookson;Daniel J. George

  • Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

    Leigh Ellis;Yan Pan;Gordon K. Smyth;Daniel J. George

  • Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

    Robert H. Vonderheide;Susan M. Domchek;Joachim L. Schultze;Daniel J. George

Frequent Co-Authors

Michael R. Harrison
Michael R. Harrison Duke University
Susan Halabi
Susan Halabi Duke University
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Eric J. Small
Eric J. Small University of California, San Francisco
Walter M. Stadler
Walter M. Stadler University of Chicago
Allan J. Pantuck
Allan J. Pantuck University of California, Los Angeles
Toni K. Choueiri
Toni K. Choueiri Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in studying Medicine in the USA, it's helpful to know about alternative online degrees and career pathways in healthcare. Many students begin by exploring nursing programs. For example, there are several absn programs that don't require teas, appealing to those wanting to become registered nurses without the added stress of entrance exams.

Another popular option is healthcare management. With flexible healthcare administration degree programs, students can develop leadership skills needed for careers in hospital or practice administration—often entirely online.

Nurses looking to advance their careers may consider specialized programs such as adn to np programs online. These bridge programs help registered nurses gain advanced practice skills and become nurse practitioners without starting over.

For those passionate about wellness, there are also excellent opportunities in nutrition. A online degree nutrition prepares students for careers in dietetics, public health, and wellness coaching. These online pathways offer flexibility while opening doors to diverse healthcare professions.

Best Scientists Citing Daniel J. George

Trending Scientists

Recently Published Articles